Studies with empagliflozin in streptozotocin-induced diabetic rats27 and results from a Phase II trial indicate beneficial effects of SGLT2 inhibition on reducing HbA1c, body weight, total daily insulin dose and hypoglycaemic events.28 Further studies with empagliflozin and other SGLT2 inhibitors are currently underway to prove their efficacy and safety in type 1 diabetes mellitus patients. Here, SLC5A2 is linked to type 1 diabetes mellitus.